Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company

Jason Mast

Editor

After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company

Jason Mast

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Feng Zhang’s qui­et spin­out snares $215M in a race for the next big CRISPR com­pa­ny

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company